Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$3.5MCash on Hand
2.8mo Cash Runway
Follow FBLG by emailGet an email when FBLG reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about FBLG, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 8, 2026 ·
Financing Entered a $1.2 million convertible debenture with Peak One Opportunity Fund, sold for $1,020,000 at a 15% original issue discount, maturing October 8, 2027 with 0% interest and fixed conversion at $0.78 per share after an Event of Default. Form 8-K · SEC filing
Sep 18, 2026 ·
Shareholder vote Stockholders approved, by 3,153,098 for and 258,217 against, the issuance of up to 8,163,266 shares on warrants under a June 2026 purchase agreement and up to 285,714 shares on H.C. Wainwright warrants. The company also closed a $0.5 million private placement with its CSO at $1.675 per share and warrant unit. Form 8-K · SEC filing · Press release
Sep 15, 2026 ·
Financing FibroBiologics agreed to sell 298,508 shares and accompanying warrants to its Chief Scientific Officer, Hamid Khoja, at $1.675 per share and warrant, for gross proceeds of about $0.5 million. The price was set at the $1.55 closing bid on September 14, 2026, plus $0.125 per warrant. Warrants are exercisable at $1.55. Form 8-K · SEC filing
Aug 24, 2026 ·
Leadership Board appointed Leigh Steinberg as a Class II director effective August 20, 2026, with a term to the 2028 annual meeting. He will receive non-employee director compensation and a standard indemnification agreement. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2026 · Phase 1/2 · Recruiting · Controlled Trial to Evaluate the Safety and Efficacy of CYWC628 (Human Dermal Fibroblast Spheroids) for the Treatment of Refractory Diabetic Foot Ulcers Compared With Standard of Care Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
FBLG holds $3.5M in cash and short-term investments (as of Jun 30, 2026) and burns about $3.8M/quarter from operations,
an estimated runway of 2.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:70 · High
Cash runway 1 months +40
ATM program on file since May 2026 +15
Shelf registration (S-3, Feb 2025) +10
Going-concern doubt in the latest 10-Q +15These factors raise substantial doubt about our ability to continue as a going concern for one year from the issuance of the financial statements included in this Quarterly Report.10-Q, Nov 2026
Raised after last reported balance sheet (Oct 2026) -10
Share count 8,989,475 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full FBLG picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for FBLG and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.